Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data

J Neurooncol. 1996 Feb;27(2):157-62. doi: 10.1007/BF00177479.

Abstract

We undertook a phase I-II trail of loco-regional mitoxantrone in 12 patients affected by malignant gliomas. Mitoxantrone was delivered at tumor recurrence by Ommaya reservoir, with 2 cycles and a 1 month interval between each cycle, in conjunction with systemic chemotherapy (8 pts) or not (4 pts). Treatment tolerability was good, and 9 of the patients showed either response or stable disease at the end of the treatment schedule. Regardless of associated chemotherapy, time to further tumor progression was at 6 months. A combination of early systemic and loco-regional chemotherapy with surgery and radiotherapy seems worth while pursuing in the therapeutic approach to malignant gliomas.

MeSH terms

  • Adult
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Catheters, Indwelling
  • Chemotherapy, Cancer, Regional Perfusion / instrumentation*
  • Electroencephalography
  • Glioma / diagnostic imaging
  • Glioma / drug therapy*
  • Humans
  • Magnetic Resonance Imaging
  • Middle Aged
  • Mitoxantrone / adverse effects
  • Mitoxantrone / therapeutic use*
  • Neoplasm Recurrence, Local / drug therapy*
  • Tomography, Emission-Computed, Single-Photon
  • Tomography, X-Ray Computed

Substances

  • Antineoplastic Agents
  • Mitoxantrone